Ohio State study: Targeted ovarian cancer therapy not cost-effective

Tuesday, March 8, 2011 - 10:10 in Health & Medicine

An analysis conducted by Ohio State University cancer researchers has found that adding the targeted therapy bevacizumab to the treatment of patients with advanced ovarian cancer is not cost effective...

Read the whole article on

More from

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net